Dino Amadori

Dino Amadori's AcademicInfluence.com Rankings

Dino Amadori

Philosophy

#8498

World Rank

#11891

Historical Rank

Logic

#5528

World Rank

#6934

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Dino Amadori's Degrees

PhD Medical Sciences University of Milan
Doctorate Medicine University of Milan

Why Is Dino Amadori Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dino Amadori's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (2006) (1169)
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization (2011) (588)
The global breast cancer burden: variations in epidemiology and survival. (2005) (558)
A case‐control study of gastric cancer and diet in Italy (1989) (548)
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. (2005) (451)
A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. (1999) (385)
Plasma AR and abiraterone-resistant prostate cancer (2015) (378)
Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. (1999) (371)
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) (2010) (350)
Modulation of mismatch repair and genomic stability by miR-155 (2010) (331)
miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis (2013) (324)
Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. (2015) (291)
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. (2011) (280)
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. (2007) (274)
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. (1991) (271)
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. (2013) (260)
Palliative sedation in end-of-life care and survival: a systematic review. (2012) (250)
A case‐control study of gastric cancer and diet in Italy: II. Association with nutrients (1990) (228)
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. (2006) (218)
Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. (2013) (212)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study (2017) (212)
Prediction of survival of patients terminally III with cancer. Results of an Italian prospective multicentric study (1995) (204)
Elf5 inhibits epithelial mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2/Slug (2012) (199)
Palliative sedation therapy does not hasten death: results from a prospective multicenter study. (2009) (189)
Impact of delirium on the short term prognosis of advanced cancer patients (2000) (178)
Pathogenesis of osteoblastic bone metastases from prostate cancer (2010) (174)
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors (2016) (171)
Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. (2011) (166)
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. (1996) (166)
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. (2013) (157)
Intake of macronutrients and risk of breast cancer (1996) (151)
High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. (2001) (149)
ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signaling (2014) (147)
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. (2013) (144)
WWOX gene restoration prevents lung cancer growth in vitro and in vivo (2005) (142)
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer (2007) (141)
A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. (1990) (138)
Guidelines on artificial nutrition versus hydration in terminal cancer patients. European Association for Palliative Care. (1996) (131)
A validation study of the WHO analgesic ladder: a two-step vs three-step strategy (2005) (127)
Prospective comparison of prognostic scores in palliative care cancer populations. (2012) (122)
Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal Cancer (2006) (121)
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. (2016) (118)
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer (2016) (117)
Body size indices and breast cancer risk before and after menopause (1996) (116)
Base transitions are the most frequent genetic changes at P53 in gastric cancer. (1993) (114)
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone (2015) (114)
p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. (1995) (114)
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers (2016) (113)
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. (2011) (107)
Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. (1998) (107)
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. (2009) (104)
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone (2014) (99)
Relevance of urine telomerase in the diagnosis of bladder cancer. (2005) (97)
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer (2014) (96)
Staging of Breast Cancer: New Recommended Standard Procedure (2002) (96)
Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. (2011) (94)
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study (2014) (93)
Fecal multiple molecular tests to detect colorectal cancer in stool. (2003) (92)
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors (2013) (92)
Occupational Exposure to Solvents and the Risk of Lymphomas (2006) (91)
Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. (1994) (91)
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. (2015) (90)
A case‐control study of gastric cancer and diet in Italy. III. Risk patterns by histologic type (1991) (88)
Mutation analysis of p53, K‐ras, and BRAF genes in colorectal cancer progression (2005) (88)
Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients (1997) (85)
Impact of palliative care unit admission on symptom control evaluated by the edmonton symptom assessment system. (2005) (85)
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. (2006) (84)
Microsatellite instability and mutations of p53 and TGF-‚RII genes in gastric cancer (1996) (83)
Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. (2014) (80)
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (2015) (79)
Androgen receptor signaling pathways as a target for breast cancer treatment. (2016) (79)
In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. (2001) (78)
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. (2001) (77)
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. (2016) (77)
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. (2017) (76)
Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: A prospective randomized study (1983) (76)
Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. (1990) (75)
Prognosis in advanced cancer. (2002) (74)
Physical activity and risk of cancers of the colon and rectum: an Italian case-control study (1999) (74)
Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC (2013) (74)
c-kit and SCF Expression in Normal and Tumor Breast Tissue (2004) (74)
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma (2013) (74)
Uncovering the genomic heterogeneity of multifocal breast cancer (2015) (73)
p16INK4A and CDH13 hypermethylation in tumor and serum of non‐small cell lung cancer patients (2006) (73)
Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model (2016) (73)
Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on a priori exposure matrices. (1996) (73)
Role of RAF/MEK/ERK pathway, p‐STAT‐3 and Mcl‐1 in sorafenib activity in human pancreatic cancer cell lines (2009) (73)
Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis (2013) (71)
Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. (2008) (70)
Schedule‐dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines (1999) (69)
Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines (2005) (69)
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer (2017) (69)
Risk of leukemia and multiple myeloma associated with exposure to benzene and other organic solvents: evidence from the Italian Multicenter Case-control study. (2008) (69)
Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on job titles. (1995) (68)
Helicobacter pylori antibodies in areas of Italy at varying gastric cancer risk. (1993) (67)
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. (2013) (67)
Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? (2008) (67)
Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. (2000) (65)
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA) (2013) (65)
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer (2016) (65)
Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact (2012) (63)
Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools? (2003) (62)
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial (2018) (62)
Mitotic catastrophe and apoptosis induced by docetaxel in hormone‐refractory prostate cancer cells (2008) (60)
Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study (2000) (60)
A new emergency in oncology: Bone metastases in breast cancer patients (Review) (2013) (60)
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. (2014) (60)
The MicroRNA-23b/27b/24 Cluster Promotes Breast Cancer Lung Metastasis by Targeting Metastasis-suppressive Gene Prosaposin (2014) (59)
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas (2016) (59)
Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (2015) (58)
Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial. (1987) (58)
Role of biological markers in the clinical outcome of colon cancer (2002) (57)
Macronutrient intake and risk of colorectal cancer in Italy (1998) (57)
Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer (2018) (56)
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide (2014) (56)
Management and potentialities of primary cancer cultures in preclinical and translational studies (2017) (55)
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC) (2014) (55)
Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. (2006) (54)
Multiple detection of genetic alterations in tumors and stool. (2001) (54)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (53)
Primary Lymphoma of the Central Nervous System (1991) (53)
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer (1999) (53)
Ipilimumab in advanced melanoma: reports of long-lasting responses (2012) (52)
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma (2016) (51)
Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study (2013) (51)
HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. (2003) (50)
A biomimetic 3D model of hypoxia-driven cancer progression (2019) (49)
Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. (2011) (49)
Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin‐2 after radical hepatic resection for colorectal liver metastases: 5‐year analysis (2004) (48)
Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. (2013) (47)
Prognostic relevance of histological grade and its components in node-negative breast cancer patients (2004) (46)
Multiple Myeloma and Work in Agriculture: Results of a Case-Control Study in Forlì, Italy (1998) (45)
Vascular endothelial growth factor and prognosis in patients with node‐negative breast cancer (2002) (45)
Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study (1997) (45)
Tumor microvessel density and prognosis in node‐negative breast cancer (2000) (44)
Urine telomerase: an important marker in the diagnosis of bladder cancer. (2004) (44)
Breast Cancer Risk Factors in Italian Women: A Multicentric Case-Control Study (1986) (43)
Prognostic Relevance of Mitotic Activity in Patients with Node-Negative Breast Cancer (2003) (43)
Multidisciplinary Approach to the Treatment of Bone Metastases: Osteo-Oncology Center, a New Organizational Model (2009) (42)
Managing chronic pain: results from an open-label study using MC5-A Calmare® device (2012) (42)
DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach (2013) (42)
Isolation of stem/progenitor cells from normal lung tissue of adult humans (2009) (41)
Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). (2010) (41)
Bone and cancer: the osteoncology. (2013) (41)
DNA amplification in human gastric carcinomas. (1993) (40)
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. (2015) (40)
In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. (2003) (40)
RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. (2006) (39)
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. (1996) (39)
Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial (1998) (39)
Establishment and characterization of a new cell line from primary human breast carcinoma (2004) (39)
Oral contraceptives and breast cancer: A cooperative Italian study (2006) (39)
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study (2012) (39)
Plasma levels of antioxidant vitamins and cholesterol in a large population sample in Central-Northern Italy (1999) (38)
Nuclear NHERF1 expression as a prognostic marker in breast cancer (2013) (38)
Efficacy of a nitric oxide–releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts (2006) (38)
EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model? (2014) (38)
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). (2011) (37)
A prognostic score for patients resected for gastric cancer. (1993) (36)
Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs (2017) (36)
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells (2005) (36)
Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy (2017) (36)
Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. (2002) (36)
Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2 (2003) (36)
Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. (2012) (36)
Atypical ductal hyperplasia of the breast: the controversial management of a borderline lesion: experience of 47 cases diagnosed at vacuum-assisted biopsy. (2006) (35)
Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents (2017) (35)
Investigating the Mechanobiology of Cancer Cell–ECM Interaction Through Collagen-Based 3D Scaffolds (2017) (35)
Circulating tumor cells in early breast cancer: A connection with vascular invasion. (2015) (35)
Ovarian cancer: natural history and metastatic pattern. (1997) (35)
In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines (2005) (34)
Quality Control for Biomarker Determination in Oncology: The Experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT) (2002) (34)
Gene methylation in rectal cancer: Predictive marker of response to chemoradiotherapy? (2013) (34)
Plasma pepsinogens, nutrients, and diet in areas of Italy at varying gastric cancer risk. (1991) (33)
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection? (2014) (33)
Perspectives on mTOR inhibitors for castration-refractory prostate cancer. (2012) (32)
Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines* (2006) (32)
First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma (2015) (32)
FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy (2012) (32)
Cancer Mortality in a Cohort of Male Agricultural Workers From Northern Italy (2004) (32)
Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer (2017) (31)
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study (2016) (31)
Potential of telomerase expression and activity in cervical specimens as a diagnostic tool (2005) (31)
Genitourinary tumors, non-prostate (2012) (31)
p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions (2002) (31)
High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients (2000) (31)
Palliative medicine and medical oncology. (2001) (31)
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial (2015) (30)
Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine (2007) (30)
Targeting bone metastatic cancer: Role of the mTOR pathway. (2014) (30)
Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer (2015) (30)
Urine telomerase activity for the detection of bladder cancer in females. (2007) (30)
Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations (2014) (30)
Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine. (2001) (29)
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. (2014) (29)
In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. (2002) (29)
Schedule-Dependent Cytotoxic Interaction between Epidoxorubicin and Gemcitabine in Human Bladder Cancer Cells in Vitro (2004) (29)
Clinical implications of microRNAs in lung cancer. (2011) (28)
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line (2008) (28)
Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukes’ C Colon Cancer (2008) (28)
Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma (2003) (28)
The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts (2016) (28)
Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells. (1990) (28)
Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity (2012) (28)
Activity of lipoplatin in tumor and in normal cells in vitro (2008) (28)
Alcohol consumption and risk of Hodgkin's lymphoma and multiple myeloma: a multicentre case-control study. (2006) (27)
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. (1993) (27)
NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells. (2008) (27)
Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care (2012) (27)
Immunosuppression in Renal Cancer: Differential Expression of Signal Transduction Molecules in Tumor-Infiltrating, Near-Tumor Tissue, and Peripheral Blood Lymphocytes (2004) (26)
Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas (2017) (26)
CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. (2014) (26)
Improved Analysis of 5-Fluorouracil and 5,6-Dihydro-5-Fluorouracil by HPLC With Diode Array Detection for Determination of Cellular Dihydropyrimidine Dehydrogenase Activity and Pharmacokinetic Profiling (2005) (26)
Hepatocellular carcinoma. Prognostic factors and survival analysis in 135 Italian patients. (1992) (26)
Role of p53 Codon 72 Arginine Allele in Cell Survival in vitro and in the Clinical Outcome of Patients with Advanced Breast Cancer (2008) (25)
Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. (1994) (25)
Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid (2012) (25)
Outcome Analysis of First‐line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG‐PET/CT (2017) (25)
Relationship Between Plasma Concentrations of 5-Fluorouracil and 5-Fluoro-5,6-Dihydrouracil and Toxicity of 5-Fluorouracil Infusions in Cancer Patients (2002) (25)
Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool. (2004) (25)
Phase II study of ortataxel in taxane-resistant breast cancer (2008) (25)
Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma (1997) (25)
Myxofibrosarcoma primary cultures: molecular and pharmacological profile (2017) (25)
Limited sampling model for the analysis of 5‐fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer (2002) (24)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial (2008) (24)
Sorafenib for the treatment of breast cancer (2017) (24)
Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer (2016) (24)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (24)
Methodological Issues in a Multicentric Study of Gastric Cancer and Diet in Italy: Study Design, Data Sources and Quality Controls (1989) (24)
Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection (2008) (24)
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer (2013) (24)
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab (2017) (24)
Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC) (2001) (24)
NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. (2003) (24)
Association of a MicroRNA / TP 53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia (2010) (24)
Loss of heterozygosity and K-ras gene mutations in gastric cancer (1993) (24)
Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients (1998) (23)
Personal Use of Hair Dyes and Hematolymphopoietic Malignancies (2005) (23)
The Mwanza Cancer Project. (2016) (23)
RANKL: A promising circulating marker for bone metastasis response. (2016) (23)
Fecal DNA for Noninvasive Diagnosis of Colorectal Cancer in Immunochemical Fecal Occult Blood Test–Positive Individuals (2010) (23)
Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. (2013) (23)
Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. (2016) (23)
Tumor Infiltrating Lymphocytes and Continuous Infusion Interleukin-2 after Metastasectomy in 61 Patients with Melanoma, Colorectal and Renal Carcinoma (2000) (23)
In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers (1995) (23)
Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. (2011) (23)
Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition (2017) (23)
Somatic frameshift mutations in the Bloom syndrome BLM gene are frequent in sporadic gastric carcinomas with microsatellite mutator phenotype (2001) (23)
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. (2011) (23)
Prognostic and predictive value of thymidine labelling index in breast cancer (2004) (22)
Iterative use of a priori exposure matrices to improve the characterization of chemical exposures in agricultural work studies. (1993) (22)
Metastatic bone disease in the era of bone-targeted therapy: clinical impact. (2013) (22)
Paclitaxel plus doxorubicin in breast cancer: an Italian experience. (1997) (22)
Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy (2013) (22)
Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines (2007) (22)
Molecular and biological features of two new human squamous and adenocarcinoma of the lung cell lines. (1998) (22)
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia (2015) (21)
Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma (2016) (21)
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. (2014) (21)
Evaluation of the cost of home care for terminally ill cancer patients (1997) (21)
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial (2015) (21)
Benefit from anthracyclines in relation to biological profiles in early breast cancer (2013) (21)
Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer. (2015) (21)
Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. (2013) (21)
Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. (1997) (20)
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) (2021) (20)
Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway (2017) (20)
ALK translocation detection in non‐small cell lung cancer cytological samples obtained by TBNA or EBUS‐TBNA (2016) (20)
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. (2015) (20)
Primary leiomyosarcoma of the bone: a case report and a review of the literature (2017) (20)
The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study (2011) (20)
Primary gastric lymphoma: a review of 45 cases. (1986) (20)
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? (2018) (20)
Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study (2011) (19)
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. (2010) (19)
Quantitative Fluorescence Determination of Long-Fragment DNA in Stool as a Marker for the Early Detection of Colorectal Cancer (2008) (19)
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy (2016) (19)
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer (2015) (19)
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer (2011) (18)
Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients (2018) (18)
Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study. (2016) (18)
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? (2018) (18)
RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study (2013) (18)
Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer. (2005) (18)
Usefulness of Immunological Detection of the Human Telomerase Reverse Transcriptase (2005) (18)
The emerging role of anti-angiogenic therapy in ovarian cancer (review). (2014) (18)
Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy (2011) (18)
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin (1999) (17)
N-Nitroso Compound Precursors and Gastric Cancer: Preliminary Data of a Study on a Group of Farm Workers (1980) (17)
Ten-year experience of the multidisciplinary Osteoncology Center (2019) (17)
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group (2006) (17)
Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. (2012) (17)
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease (2013) (17)
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. (2011) (17)
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition (2019) (16)
Oral vinorelbine in metastatic breast cancer: Long-term results of 2 multicenter phase II studies (2004) (16)
Role of Androgen and Estrogen Receptors as Prognostic and Potential Predictive Markers of Ductal Carcinoma in Situ of the Breast (2015) (16)
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. (2012) (16)
Steroid receptor enhancement by natural interferon-β in advanced breast cancer (1993) (16)
Patterns and determinants of receipt of follow-up mammography and/or clinical examination in a cohort of Italian breast cancer survivors (2016) (16)
Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life. (2011) (15)
High-dose etoposide and autologous bone marrow transplantation as intensification treatment in small cell lung cancer: a pilot study. (1989) (15)
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence (2014) (15)
42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC) (2004) (15)
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. (2009) (15)
Cell kinetics and prognosis in gastric cancer (1993) (15)
Effect of Small Molecules Modulating Androgen Receptor (SARMs) in Human Prostate Cancer Models (2013) (15)
First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer (2014) (15)
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients (1999) (15)
In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. (2010) (15)
Comparison between different cell kinetic variables in human breast cancer. (2000) (15)
In vivo manipulation of human breast cancer growth by estrogens and growth hormone: Kinetic and clinical results (1990) (14)
Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer. (1992) (14)
Secondary lung tumors in hematological patients. (2005) (14)
A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. (1996) (14)
Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study (2011) (14)
Prognostic relevance of mitotic activity in patients with node-negative breast cancer (2003) (14)
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience (2006) (14)
Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer (2010) (13)
Clinical Relevance of Cell Kinetics in Breast Cancer (1993) (13)
Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT). (2005) (13)
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer (2017) (13)
Palliative care in advanced cancer. (2005) (13)
The challenge of sustainability in healthcare systems: Frequency and cost of inappropriate patterns of breast cancer care (the E.Pic.A study). (2017) (13)
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? (2018) (13)
Do Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer? (2006) (13)
ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. (2012) (13)
Gemcitabine and taxanes in metastatic breast cancer. (2006) (13)
Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis (2008) (13)
Evaluation of cost of home therapy for patients with terminal diseases (1998) (12)
Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics (2007) (12)
Disease family history and modification of breast cancer risk in common BRCA2 variants. (2008) (12)
Bone metastases detection by circulating biomarkers: OPG and RANK-L. (2011) (12)
Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue (2013) (12)
Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature (2014) (12)
The current role of telomerase in the diagnosis of bladder cancer (2009) (12)
Potentiation of Antiproliferative Drug Activity by Lonidamine in Hepatocellular Carcinoma Cells (2003) (12)
Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients. (2014) (12)
Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model (2016) (12)
Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). (1996) (12)
Modulation of drug cytotoxicity by iressa (ZD1839) in pancreatic cancer cell lines (2005) (11)
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study. (1998) (11)
Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines (2009) (11)
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial (2020) (11)
[Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines. (2013) (11)
New Biomarkers to Predict the Evolution of In Situ Breast Cancers (2014) (11)
Quality Assurance for Steroid Receptor Assay in Human Breast Cancer: Six Years Experience of the Italian Committee (1985) (11)
Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer (2016) (11)
Molecular genetics and in vitro sensitivity of a new human cell line, KKP, from a gastric adenocarcinoma. (1998) (11)
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy (2015) (11)
Different genome organization in two new cell lines established from human gastric carcinoma. (1998) (11)
Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue (2014) (11)
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
Docetaxel–ST1481 sequence exerts a potent cytotoxic activity on hormone‐resistant prostate cancer cells by reducing drug resistance‐related gene expression (2009) (10)
MicroRNAs and dendritic cell-based vaccination in melanoma patients (2014) (10)
Abstract P5-18-01: Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study (2012) (10)
Time‐Dependent Pharmacokinetics of 5‐Fluorouracil and Association With Treatment Tolerability in the Adjuvant Setting of Colorectal Cancer (2012) (10)
Reply: Prediction of survival in terminally ill cancer patients: why we cannot avoid an evidence-based palliative medicine (2002) (10)
Improved Stool DNA Integrity Method for Early Colorectal Cancer Diagnosis (2014) (10)
Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial (2020) (10)
A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. (2013) (10)
Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approaches (2011) (10)
Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial (2016) (9)
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma. (2018) (9)
Pathology and oncology in Africa: education and training for the future in cancer research– East African Regional Meeting (2015) (9)
Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial. (2009) (9)
Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): Final results from the Itaca randomized clinical trial. (2013) (9)
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial (2020) (9)
Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania (2017) (9)
Phase I Trial of Panobinostat (LBH589) in Combination with Trastuzumab in Pretreated HER2-Positive Metastatic Breast Cancer (mBC): Preliminary Safety, Efficacy and Pharmacokinetic Results. (2009) (9)
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer (2018) (9)
Breast cancer, locally advanced and metastatic (2012) (9)
Staging of breast cancer: it is time to break with tradition and initiate the evidence-based-medicine age. (2001) (9)
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial (2017) (9)
Phase I Study of Paclitaxel and Uracil plus Tegafur Combination in Patients with Pretreated Metastatic Breast Cancer: Drug Sequencing Based on Preclinical Modelling Studies (2007) (8)
Tumorlets in familial history of bronchopulmonary carcinoid. (2011) (8)
Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies (2019) (8)
Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. (2014) (8)
Chromosomal alterations, biological features and in vitro chemosensitivity of SCLC-R1, a new cell line from human metastatic small cell lung carcinoma. (1998) (8)
Gastric Cancer: Histopathologic Patterns According to Lauren's Classification in a High-Risk Area and Distribution by Residence (1986) (8)
Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential (2012) (8)
Biofunctional characteristics of in situ and invasive breast carcinoma (2013) (8)
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab (2018) (8)
GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. (2011) (8)
Adjuvant Chemotherapy with Fluorouracil and ccnu in Colon Cancer. Results of a Multicentric Randomized Study (1989) (8)
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer (2021) (8)
Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables (2004) (8)
Gastric cancer mortality in the spouses of patients who died from gastric cancer. (2002) (7)
Hospital versus population controls in a retrospective study on diet and stomach cancer (1995) (7)
Consensus Development Conference: Assessment of the Quality of Life in Cancer Clinical Trials (1992) (7)
Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen (2001) (7)
Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer. (2012) (7)
Relation between food habits and p53 mutational spectrum in gastric cancer patients. (2000) (7)
Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. (2014) (7)
The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer. (1996) (7)
An efficient method for culturing human breast carcinoma to evaluate antiblastic drug activityin vitro: Experience on 136 primary cancers and on 116 recurrences (2005) (7)
Early detection of cardiotoxicity in chemotherapy-treated patients from real-time 3D echocardiography (2013) (7)
Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report (2015) (7)
Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. (2014) (7)
GM-CSF production in human adenocarcinoma cell lines. (1993) (7)
Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. (2011) (7)
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer. (2015) (7)
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial (2018) (7)
Doxorubicin, Paclitaxel and Gemcitabine: a Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer (2003) (7)
Flow-Cytometric Determination of Tumor Cells in Lymph Nodes1 (2002) (6)
Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method (2001) (6)
Lineage‐specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture (2020) (6)
Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients? (2014) (6)
Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations (2008) (6)
Activity of different anthracycline formulations in hormone‐refractory prostate cancer cell lines: Role of golgi apparatus (2011) (6)
Gastric Carcinoma: Preliminary Data of a Cooperative Program for Early Diagnosis (1980) (6)
Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review (2011) (6)
Hemangioblastoma of the Gastrointestinal Tract: A First Case (2013) (6)
In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines (2005) (6)
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? (2013) (6)
Relative and absolute cancer mortality of women in agriculture in northern Italy (2005) (6)
Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age (2018) (6)
Pancreatic resection for metastases from renal cancer: long term outcome after surgery and immunotherapy approach - single center experience. (2012) (6)
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report (2016) (6)
Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study (2005) (6)
Comparison between differentcell kinetic variables in human breast cancer (2000) (6)
Inhibition of growth of breast cancer cells in vitro by the ribosome-inactivating protein saporin 6. (1991) (6)
Gastric cancer: epidemiologic and biological aspects. (1998) (5)
High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). (2015) (5)
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models (2009) (5)
Lonidamine in modulation of response to adriamycin in advanced breast cancer. Preliminary results (1994) (5)
Prolonged 18FDG‐PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd‐G) (2011) (5)
First line treatment of HER-2/neu positive advanced breast cancer patients with liposomal doxorubicin (Myocet), docetaxel and trastuzumab. A phase I-II study. (2006) (5)
Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life (2011) (5)
Simultaneous determination of apoptosis and surface antigen expression in tumor adherent cells. (2001) (5)
A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon. (1994) (5)
INCREASE OF REPORTS OF SUSPECTED ADVERSE DRUG REACTIONS IN ONCOLOGY Original Article (2014) (5)
Breast carcinoma stage in relation to time interval since last mammography (1997) (5)
Evaluation of toxicity in 22 patients treated with subcutaneous interleukin-2, alpha-interferon with and without chemotherapy. (1992) (5)
Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer (2018) (5)
A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. (2011) (5)
[18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. (2010) (5)
Combined 4-hydroxy-ifosfamide and vinorelbine treatment in established and primary human breast cell cultures. (2000) (5)
Establishment and characterization of two new cell lines derived from human metastatic breast carcinomas (1997) (5)
P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer. (2011) (5)
Phase II trial of nonpegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study. (2010) (4)
Cell kinetics and hormonal features in relation to pathological stage in breast cancer (1991) (4)
Metastatic Bone Disease in the Era of Bone-Targeted Therapy: Clinical Impact (2013) (4)
Saporin 6 and lonidamine in primary cell cultures from human breast carcinomas: a synergistic effect. (1997) (4)
Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer (2012) (4)
The surgical pathology laboratory in Mwanza, Tanzania: a survey on the reproducibility of diagnoses after the first years of autonomous activity (2017) (4)
Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. (2013) (4)
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (2021) (4)
Persistence of efficacy of ondansetrom (DMD) plus dexanethasone (DEX) VS metoclopramide (MTC) plus dex and diphennydramine (DIP) in acute emesis during three consecutive cycles of cisplatin (CDDP) chemotherapy (CT) (1993) (4)
Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs (2018) (4)
Safety and efficacy of Scrambler therapy for cancer pain. (2010) (4)
Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers. (2018) (4)
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines. (2017) (4)
Docetaxel Followed by Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer: A Phase I Study (2002) (4)
A new cell line from human infiltrating ductal carcinoma of the breast: establishment and characterization (2005) (4)
An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+ Advanced Breast Cancer (ABC). (2009) (4)
Inflammatory breast carcinoma: results from sixteen patients treated with chemo-radiotherapy and surgery. (1984) (4)
114PMolecular imaging with 18F-fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): A European TRANSCAN program (2017) (4)
[Prevalence of anemia in oncologic patients treated with chemotherapy. Italian survey at the national level]. (2001) (4)
Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT (2017) (4)
Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients. (2016) (4)
Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR) (2016) (4)
Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial. (2019) (4)
Multicentric case-control study on diet and gastric cancer in Italy (1988) (4)
Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial (2020) (4)
Evaluating the appropriateness of chemotherapy in a low‐resource cancer centre in sub‐Saharan Africa (2019) (4)
[Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]. (2003) (4)
Quality Control for Estrogen and Progesterone Receptor Assay in Human Breast Cancer: The Influence of Computation Methods on Intra and Interlaboratory Variability (1985) (4)
Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib. (2015) (4)
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions (2016) (4)
Population-based screening for hereditary breast cancer in a region of North-Central Italy. (2002) (4)
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. (2005) (4)
Explaining the aggressiveness of breast cancer in sub-Saharan African patients (2019) (4)
Cyto-morphological aspects and cyto-histological correlations in pre-neoplastic alterations and in malignancies of gastric mucosa (1981) (3)
Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma (2011) (3)
EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab (2015) (3)
Intraductal papillomas: diagnostic and surgical procedures. (1985) (3)
Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects (2010) (3)
Long-term Complete Response in a Patient with Liver Metastases from Breast Cancer Treated with Metronomic Chemotherapy (2014) (3)
HIF-1 alpha expression as a predictor of bevacizumab efficacy in metastatic colorectal cancer. (2015) (3)
RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination. (2009) (3)
Topical prostaglandin E2 and chemo- and radio-induced oral mucositis. (1996) (3)
Erratum: Prognostic relevance of mitotic activity in patients with node-negative breast cancer (Modern Pathology (2003) 16, 11 (1067-1075)) (2004) (3)
Frequency and Determinants of Lymphadenectomy in Endometrial Carcinoma: A Population-Based Study From Northern Italy (2001) (3)
Stimulation of Human Breast Cancer in Vivo (1993) (3)
Is an Antiemetic Prophylactic Treatment Needed for Patients Submitted to Consecutive Days of 5-fluorouracil? An Observational Study (2001) (3)
Multiple Primary Tumors in a Family with Li-Fraumeni Syndrome with a TP53 Germline Mutation Identified by Next-Generation Sequencing (2016) (3)
Cathepsin D versus Other Prognostic Factors in Breast Cancer. Results and Controversies of a Multicenter Study on 2575 Cases (1996) (3)
5075 Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer (2009) (3)
Translational study of the activity of liposomal doxorubicin formulations in hormone-refractory prostate cancer. (2009) (3)
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer (2010) (3)
[Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases]. (1977) (3)
Study of the c-Ha-ras-1 locus polymorphism in an Italian population with high incidence of gastric cancer. (1988) (3)
Impact of insulin resistance (IR) on the prognosis of metastatic breast cancer (MBC) patients treated with first-line chemotherapy (CT). (2014) (3)
Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer. (2009) (3)
What can we learn from the ZOOM trial?--Authors' reply. (2013) (3)
Steroid receptor enhancement by natural interferon-beta in advanced breast cancer. (1993) (3)
An Efficient Method for Culturing Human Breast Epithelium: Analysis of Results (1991) (3)
Interactive training for the management of breast cancer in general practice in Europe. (2002) (2)
Reply to E. Schildmann et al (2012) (2)
1147 Gemcitabine in resistant stage IV bladder cancer: A phase II study (1995) (2)
Correction: EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model? (2015) (2)
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer (2008) (2)
[MAP (medroxyprogesterone) in the therapy of breast carcinoma]. (1972) (2)
Abstract P3-13-02: Phase II randomised clinical study of first line chemotherapy plus metformin versus first line chemotherapy alone in HER2 negative, non diabetic, metastatic breast cancer patients: Final results of the MYME study (2015) (2)
Adenocarcinoma of the lung and venous thromboembolic events: a monoinstitutional, retrospective evaluation. (2015) (2)
Different mechanisms involved in the activity of BAY 43-9006 (Sorafenib) in human pancreatic cancer cell lines (2008) (2)
Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review. (2010) (2)
Circulating levels of RANK/RANKL and OPG in patients with bone metastasis treated with zoledronic acid: A prospective study. (2011) (2)
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients (2009) (2)
A Retrospective Study of Fam Regimen in 38 Patients with Advanced Gastric Cancer (1984) (2)
Efficacy of bevacizumab in second-line versus first-line treatment of metastatic colorectal cancer: Results from a new methodological approach based on the ITACa strategy trial. (2017) (2)
Radioligand-Labeled Binding Assay and Immunochemical Assay for Estrogen Receptor in 115 Human Breast Cancers (1988) (2)
Abstract PD6-04: HOHO study: How European and US young women cope with breast cancer and fertility concerns (2017) (2)
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. (2009) (2)
Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia (2008) (2)
CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model (2017) (2)
Cytokinetic studies and treatment results of estrogens followed by chemotherapy in locally advanced (LABC) and metastatic (MBC) human breast cancer (1986) (2)
Survival prediction for terminally ill patients with cancer: Revision of palliative prognostic score with incorporation of delirium. (2011) (2)
H33Venous thromboembolic events in advanced adenocarcinoma of the lung: impact on prognosis according to platinum therapies and presence of driver mutations (2015) (2)
Biology matters: the clinical impact of single-receptor discordance on breast cancer. (2013) (2)
Prognostic factors and survival in non-Hodgkin's lymphomas: the experience of the Istituto Oncologico Romagnolo (IOR). (1994) (1)
Female breast cancers (T1-2, N0, M0, HR+, HER2−) with an intermediate genetic-based recurrence risk: a real-world estimate in Italy (2019) (1)
PD05-01: Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. (2011) (1)
A phase II comparative study of metformin plus first-line chemotherapy (CT) versus CT alone in HER2-negative, insulin-resistant (IR), nondiabetic metastatic breast cancer (MBC). (2010) (1)
Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone) (2012) (1)
DESCRIBING TREATMENT, TREATMENT OUTCOMES, RESOURCE USE AND QUALITY OF LIFE OF ADVANCED NSCLC PATIENTS - THE LUNG CANCER ECONOMICS AND OUTCOMES RESEARCH (LUCEOR) STUDIES (2011) (1)
Erratum to: Managing chronic pain: results from an open-label study using MC5-A Calmare® device (2013) (1)
Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer. (2009) (1)
L12Association with programmed death ligand-1 (PDL-1) expression and Helicobacter Pylori infection in patients with non-diffuse type gastric carcinoma (2015) (1)
[Telomerase activity: a molecular marker for early diagnosis of bladder tumor]. (2007) (1)
EAP in advanced gastric cancer. (1993) (1)
Influence of chemotherapy on the evaluation of breast cancer–diet link (1999) (1)
Once-weekly epoetin beta treatment in anemic patients with breast cancer receiving chemotherapy: Interim analysis of a multicenter, single arm study (2007) (1)
[Cytological aspects of atrophic gastritis associated with gastric carcinoma]. (1973) (1)
Trastuzumab-induced cardiotoxicity in early breast cancer: Evaluation of possible risk and protective factors. (2012) (1)
Early gastric cancer detection in four areas at different gastric cancer death rate (1981) (1)
The cancer registry in the monitoring of cervical screening practice: the neglected value of the Pap smear in patients diagnosed with CIN3 on biopsy. (1998) (1)
Comparison between immature and mature dendritic cells in a vaccination trial. (2004) (1)
Proportion of gastric cancer risk attributable to diet in Italy (1991) (1)
Abstract CT135: Uncovering the genomic heterogeneity of multifocal breast cancer (2015) (1)
Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT. (2013) (1)
Italian perspective bone metastases (BM) database: The first one-year experience. (2016) (1)
Cytosol cathepsin-D content and proliferative activity of human breast cancer (2005) (1)
The Comprehensive Cancer Care Network of Romagna: the opportunities generated by the OECI accreditation program. (2016) (1)
Hemangioblastoma of the Gastrointestinal Tract (2013) (1)
Medication reconciliation in cancer day hospital. (2015) (1)
Erratum to: Is a clear benefit in survival enough to modify patient access to the surgery service? A retrospective analysis in a cohort of gastric cancer patients (2014) (1)
Feasibility of a Cell Kinetic-Based Adjuvant Chemotherapy Trial in Axillary Node-Negative Breast Cancer (2000) (1)
Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid (2012) (1)
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease (2013) (1)
Doxorubicin (Dox), cyclophosphamide (Cyc) and weekly docetaxel (Doc) as first-line treatment of advanced breast cancer (ABC) (2007) (1)
Erratum: Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer (British Journal of Cancer (2004) 92 (24-29) DOI: 10.1038/sj.bjc.6602276) (2005) (1)
Setting Up a Medical Oncology Educational Program in Sub-Saharan Africa (2021) (1)
DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach (2013) (1)
A randomized phase II study of pemetrexed-carboplatin and gemcitabine-vinorelbine in patients with anthracycline- and taxane-pretreated advanced breast cancer. (2011) (1)
A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer. (2016) (1)
Prospective use of tumor proliferative activity for adjuvant therapy in node-negative breast cancer patients (1997) (1)
Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer? (2017) (1)
Liver Metastases from Gastric Carcinoma: Report of a Patient Treated with Adoptive Immunotherapy (Tumor-Infiltrating Lymphocytes plus Interleukin-2 and Subsequently Local-Regional Lymphokine-Activated Killer Cells plus inTerleukin-2) (1995) (1)
Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC). (2017) (1)
BP129 INSULIN RESISTANCE (IR) AND PROGNOSIS OF METASTATIC BREAST CANCER (MBC) PATIENTS (2015) (1)
Prognostic and predictive role of circulating eNOS and EPHB4 in metastatic colorectal cancer patients receiving bevacizumab. (2016) (1)
[Doxorubicin and paclitaxel versus 5-fluorouracil, doxorubicin and cyclophosphamide as first-line treatment in women with metastatic breast carcinoma: final results of a phase III multicenter randomized trial]. (2001) (1)
[Role of biological indicators in the therapeutic decision in breast carcinoma]. (1995) (1)
MC13-0067 Association between Kras mutation in circulating cell-free tumor DNA and clinical progression of colorectal cancer in patients receiving cetuximab (2013) (0)
Relevance of Traditional CEA and CA15-3 and Bone Turnover Markers in Predicting Bone Relapse in Breast Cancer Patients. (2009) (0)
Zoledronic acid enhances docetaxel-induced apoptosis through pMEK and MCL-1 inhibition in hormone sensitive prostate carcinoma cell lines (2008) (0)
Effect of neutropenia with adjuvant epirubicin-CMF on survival in patients with node-negative or 1 to 3 node-positive rapidly proliferating breast cancer. (2011) (0)
Editorial Expression of Concern: WWOX gene restoration prevents lung cancer growth in vitro and in vivo (2017) (0)
Adjuvant CMF for patients with node-negative, rapidly proliferating breast cancer. (2000) (0)
Abstract P1-13-04: Immunohistochemical Evaluation of RANK/RANKL/OPG Axis and CXCR4 in Primary Breast Cancer and Their Role in Bone Metastasization (2010) (0)
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab (2017) (0)
Abstract B262: Tyrosine kinase inhibitors induce rapid cellular alterations in breast cancer cells in vitro (2009) (0)
Abstract A83: Liposomal doxorubicin induces Golgi‐dependent apoptosis in hormone‐refractory prostate cancer cell lines (HRPC) (2009) (0)
A52Everolimus activity on breast cancer and bone cell cocultures (2015) (0)
Management and potentialities of primary cancer cultures in preclinical and translational studies (2017) (0)
Impact of Ki67 and progesterone receptor on PFS with cyclin-dependent kinase 4/6 inhibitors in HER2-negative advanced breast cancer: A real world mono-institutional experience (2020) (0)
Exploratory study of histopathological characteristics of cervical cancer in an African (Tanzania) population. (2013) (0)
Breast cancer screening (1998) (0)
Early diagnosis program for cervical cancer in Tanzania: The “Vanda Project”. (2013) (0)
222 P53-mediated apoptosis induced by NCX 4040, a nitric oxide-releasing aspirin derivative, in human colon cancer cell lines (2004) (0)
TIL culture and expansion from 42 human tumors. Reinfusion for immunoadoptive therapy in 15 patients: Preliminary data (1995) (0)
Abstract 2241: Role of tissue markers in the prediction of bone metastases from breast cancer (2010) (0)
Rese Fec Imm Danie Waine Abst Intro The (2010) (0)
Multidisciplinary Osteo-Oncology Center for the management of bone metastases (2008) (0)
Trefoil factor 1 as a predictive factor of bone metastases in breast cancer. (2013) (0)
Diagnostic role of new circulating markers in bone metastases from breast cancer (2008) (0)
P1-12-17: Fluorescent In Situ Hybridization Evaluation of HER2 Status in Tumors with Chromosome 17 Polysomy. (2011) (0)
P3.02-007 Circulating miRNAs as Prognostic Biomarkers in Resected Early-Stages Non-Small-Cell Lung Cancer (2017) (0)
232 In vitro and in vivo antitumor efficacy of NCX-4040, a nitric oxide-releasing non-steroidal anti-inflammatory drug, in combination with antineoplastic drugs on human colon cancer lines (2004) (0)
Doxorubicin and cyclophosphamide adjuvant chemotherapy is no more effective than cyclophosphamide, methotrexate, and 5-fluorouracil for premenopausal axillary lymph node positive breast cancer (2001) (0)
Abstract 5167: A new panel of tissue markers for the prediction of bone metastatization from primary breast cancer (2011) (0)
Zoledronic acid effect on circulating RANK/RANK-l/OPG axis in cancer patients. (2017) (0)
Intra-arterial Chemoimmunotherapy of Liver Metastases from Colorectal Cancer (2002) (0)
Investigating the Mechanobiology of Cancer Cell–ECM Interaction Through Collagen-Based 3D Scaffolds (2017) (0)
Intra-arterial Chemotherapy of Inoperable Pancreatic Cancer (2002) (0)
Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report (2015) (0)
9080 POSTER Activity of Ixabepilone and Cisplatin Combination in Chemo-naive Stage IIIB/IV NSCLC – a Phase lb Study (2011) (0)
Suppl_stat_methods_ID_TAM-19-09-430_R1 – Supplemental material for Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial (2020) (0)
Effect of vaccination with autologous tumor-loaded dendritic cells on intratumoral regulatory T cells in metastatic melanoma patients. (2013) (0)
Vaccination with mature (mDC) and immature (iDC) dendritic cells pulsed with autologous tumor lysate in patients with advanced melanoma and renal cell carcinoma (2004) (0)
The role of serum chromogranin A (CgA) in patients with small cell lung cancer. (2004) (0)
Abstract P6-05-02: Clinical-Pathological Features of All Nodules with the Same Histotype Affect Systemic Adjuvant Treatment Decision in Multifocal and Multicentric Breast Cancer (2010) (0)
N06Chemotherapy near end-of life: aiming for appropriateness at the Cancer Institute of Romagna (IRST IRCCS) (2015) (0)
Session A: Early and advanced Breast Cancer A1 IMPORTANCE OF 5-FU (5-FLUOROURACIL) INFUSION DURATION AND TOXICITY DURING CMF (CYCLOFOSFAMIDE, METHOTREXATE, 5 FLUOROURACIL) ADMINISTRATION IN ADJUVANT SETTING OF BREAST CANCER (2005) (0)
Prognostic role of inflammatory index in head and neck squamous-cell carcinoma patients in first line chemotherapy. (2018) (0)
Circulating AR copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel. (2016) (0)
Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab (2014) (0)
RANK/RANKL/OPG as Predictive Factors of Bone Response in Patients with Bone Metastases from Solid Tumours (2015) (0)
Randomized phase III trial of adjuvant epicirubicin (E) followed by cyclophosphamide, methotrexate, and fluorouracil (CMF) or CMF followed by E in patients with N- or ≤ 3 N+ rapidly proliferating breast cancer (RPBC). (2016) (0)
L46Exploratory study of histopathological characteristics of Hepatocellular carcinoma (HCC) in African (Tanzania) and Caucasian (Italian) population (2015) (0)
Emerging strategies in medical oncology: Introduction (1997) (0)
Additional file 4: of eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial (2015) (0)
The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer. (2019) (0)
High neutrophil to lymphocyte ratio persistent during first-line chemotherapy to predict clinical outcome in patients with advanced urothelial cancer. (2014) (0)
263PDTIME TO INITIATION OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH RAPIDLY PROLIFERATING EARLY BREAST CANCER. (2014) (0)
Navoban (tropisetron): reducing the distress of the first-time chemotherapy patient. (1995) (0)
Mini-gene profiling for the prediction of bone metastases in breast cancer patients. (2011) (0)
Additional file 2: of eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial (2015) (0)
Increased choline uptake in androgen receptor (AR) copy number gain castration-resistant prostate cancers (CRPC) (2016) (0)
The Activity of Everolimus in a Coculture Model of Breast Cancer and Bone Cells (2015) (0)
Lymphopeniaand clinical outcome ofelderlypatients treated with sunitinib for metastatic renal cell cancer (2014) (0)
Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM). (2017) (0)
Accuracy in targeted therapy prescription: An observational retrospective study. (2011) (0)
Abstract B44: Clinical relevance of androgen and estrogen receptors in patients with ductal carcinoma in situ of the breast treated with surgery and radiotherapy (2016) (0)
Serum angiogenesis associated proteins and clinical outcome in metastatic colorectal cancer patients receiving bevacizumab. (2018) (0)
[Report of the preliminary results of screening for uterine tumors in the province of Forlì]. (1968) (0)
Exploratory study of histopathological and biomolecular characteristics of breast cancer in two different populations: African (Tanzania) and Caucasian (Italy). (2012) (0)
Erratum: Pathogenesis of osteoblastic bone metastases from prostate cancer (2010) (0)
P2-19-04: Changes in Adjuvant Treatment of Early Breast Cancer in Italy between 2000 and 2008. The NEMESI Study Versus the NORA Study. (2011) (0)
455PMetastatic neuroendocrine neoplasia (mNEN) treatments in over 70 years (y) old patients: A retrospective outcome analysis (2017) (0)
Association between insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) and prognosis in patients with metastatic breast cancer (MBC). (2017) (0)
Survey of the sociodemographic and motivational profile of volunteers in oncology. (2006) (0)
[Anatomo-clinical remarks on a case of chemodectoma of the tympanic glomus]. (1968) (0)
R36First Prospective Bone Metastases (BM) Data Base: One-Year experience (2015) (0)
Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer. (2010) (0)
Phase II randomised clinical study of metformin plus chemotherapy vs chemotherapy alone in HER2 negative metastatic breast cancer: final results of the MYME trial (2016) (0)
[Fine needle aspiration of breast diseases (author's transl)]. (1980) (0)
Prognostic role of aspartate aminotransferase-lymphocyte ratio index (ALRI) in patients with metastatic colorectal cancer: results from the ITACa trial. (2017) (0)
Effectiveness of dermatologic evaluation in the management of cancer patients. (2015) (0)
An initiative to assess the quality of Tanzanian cervical cancer specimens for HPV and telomerase detection. (2021) (0)
Metastatic NSCLC: Can molecular biology guide surgical decision making? (2012) (0)
Combination Chemotherapy in Advanced Ovarian Carcinoma (1986) (0)
Association between c-myc amplification and other biologic features and prognosis in primary breast cancer. (2010) (0)
Impact of body mass index (BMI) on the prognosis of women with high-risk early breast cancer (BC) receiving adjuvant chemotherapy (CT). (2017) (0)
P07Recombinant granulocyte colony-stimulating factors (rG-CSFs) in the management of NEUtropenia induced by anthracyclines and ifosfamide in patients with soft tissue SARcomas (NEUSAR) (2016) (0)
[Relationship between cytosol CEA and clinico-pathologic and biologic parameters in 167 cases if primary carcinoma of the breast]. (1990) (0)
Gemcitabine as an endovesical treatment in patients with BCG-refractory superficial bladder carcinoma (2005) (0)
Abstract 4901: Preliminary investigation of circulating NSCLC cells using dielectrophoresis-based instrumentation (2011) (0)
[Production and diffusion of scientific results in oncology]. (2004) (0)
Subject Index Vol. 27, 2006 (2006) (0)
Cell cycle perturbation and cytotoxic activity of docetaxel/gemcitabine combinations on human non-small cell lung cancer (NSCLC) cell lines (1997) (0)
HER-2 Expression a nd C ell P roliferation: P rognostic M arkers in P atients W ith N ode-Negative B reast C ancer (2003) (0)
Evaluation of prognostic role of inflammatory index in glioblastoma multiforme patients undergoing to concomitant radio-chemotherapy. (2019) (0)
KRAS, BRAF, PIK3CA, and human papilloma virus (HPV) status in squamous cell anal carcinoma (SCAC). (2017) (0)
Case histories: breast cancer (2011) (0)
Gene mutations and resistance to cisplatin and doxorubicin in cell lines derived from different human tumor types (1997) (0)
F073-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA (2015) (0)
Chromogranin A predicts outcome in prostate cancer (2014) (0)
560PIMPACT OF PRE-TREATMENT LACTATE DEHYDROGENASE (LDH) LEVELS ON PROGNOSIS AND BEVACIZUMAB EFFICACY IN ADVANCED COLORECTAL CANCER PATIENTS. (2014) (0)
Detection and recovery of circulating tumor cells in early breast cancer: A connection with vascular invasion. (2015) (0)
A61Tumor-stroma cross-talk in the study of the osteoclastogenic potential of a metastatic breast cancer cell line: a coculture system (2015) (0)
PR and Ki67 in primary tumors and metastatic sites as biomarkers for benefit from endocrine therapy (ET) in metastatic breast cancer (mBC). (2013) (0)
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? (2018) (0)
Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC). (2011) (0)
S32English Language in Oncology: a Targeted Training Programme for the Researchers and Healthcare Professionals of IRST IRCCS (Romagna Oncology Network, Italy) (2016) (0)
Adjuvant polychemotherapy vs control for node-negative, rapidly proliferating breast cancer: Combined analysis of two phase III trials (2003) (0)
Preclinical evaluation of the interaction among doxorubicin, paclitaxel and gemcitabine in human breast cancer cell line (1997) (0)
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence (2014) (0)
Efficacy results of first-line chemotherapy re-challenge in sensitive small cell lung cancer (SCLC): A retrospective multicenter analysis. (2017) (0)
Establishment of a “near patient model” of dedifferentiated liposarcoma: A proof of concept of the usefulness of zebrafish model. (2016) (0)
Abstract C100: KRAS mutations in circulating cell-free DNA of colorectal cancer patients in progression after MoAb anti-EGFR therapy. (2013) (0)
Session D: Organization D1 ORGANIZATIONAL MODEL OF CENTRALIZED PHARMACY FOR THE PREPARATION OF CANCER THERAPIES PERSPECTIVE (2004) (0)
Supplementary Figure S1 (2015) (0)
Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab (2014) (0)
Association of polymorphisms of genes involved in the androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population (2005) (0)
Prognostic relevance of androgen and estrogen receptors in ductal carcinoma in situ evolution. (2015) (0)
Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer. (2016) (0)
Effect of routine mammography practice on tumour size of a registry-based series of breast cancer cases compared with those observed in a screening cohort. (1997) (0)
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. (2013) (0)
PP 20 Methylation profile and chemoradioresistance in rectal cancer (2011) (0)
First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer (2014) (0)
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients (2013) (0)
Additional file 5: of eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial (2015) (0)
124PRole of circulating miRNAs as prognostic biomarkers in resected early-stage non-small cell lung cancer (2017) (0)
R50“Share & Meet” project: an innovative telemedicine solution for remotization of pathology and e-oncology (2015) (0)
Multicentric survey on dose reduction in cancer drug therapy: Detection and measurement of critical phenomena as potential indicators of suspected adverse reactions. (2013) (0)
[Cytologic reports of MAC (Malignancy Associated Changes sec. Nieburgs) in cases of gynecologic neoplasms]. (1971) (0)
RANKL circulating levels in the evaluation of bone response in breast cancer (BC) patients. (2014) (0)
Right- versus left-side metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy. (2017) (0)
FOLFOX4/XELOX in stage II-III colon cancer: Early survival data of the Italian three or six colon adjuvant (TOSCA) trial. (2017) (0)
Intervention model for cancer control in a low-income African area. (2011) (0)
Process and outcome indicators for evaluation of surgical activity in a high-risk gastric cancer area. (2011) (0)
[Atypical dysplasia and carcinoma of the portio. Review of colposcopic and cytologic studies in 119 cases]. (1982) (0)
Predictive value of VEGF gene polymorphisms in metastatic colorectal cancer patients treated with a bevacizumab-based chemotherapy. (2013) (0)
Intra-Arterial Chemotherapy for the Treatment of Liver Metastases from Colorectal Cancer (2002) (0)
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial (2015) (0)
Actual trends in the epidemiology of gastric cancer (1989) (0)
Correlation of stomatitis and cutaneous toxicity with clinical outcome in patients with metastatic renal cell carcinoma treated with everolimus. (2013) (0)
Is Vit D serum concentration related to Italian and Tanzanian breast cancer cases? (2015) (0)
Biofunctional characteristics of in situ and invasive breast carcinoma (2013) (0)
Potential usefulness of OPG, a member of the tumor necrosis factor receptor superfamily, for the early diagnosis of bone metastasis in breast cancer patients. (2016) (0)
Unusal lung damage associated with pemetrexed in malignant pleural mesothelioma: A case report (2008) (0)
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial (2017) (0)
PP 13 Urine cell free DNA integrity as a marker for early diagnosis of non invasive bladder cancer (2011) (0)
Early response assessment and bone flare phenomenon on 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) treated with abiraterone acetate. (2013) (0)
P-283Impact of second-line cetuximab-containing therapy in patients with KRAS wild type metastatic colorectal cancer: results from ITACa trial (2015) (0)
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study. (2016) (0)
A 5′-truncated c-myc gene variant not associated with a risk of cancer (1991) (0)
Molecular characterization and pharmacological profile of myxofibrosarcoma primary cultures. (2017) (0)
FL-DNA approach for noninvasive early diagnosis of colorectal cancer in FOBT-screened patients. (2016) (0)
87 NTX and VEGF in cancer patients with bone metastases treated with zoledronic acid (2010) (0)
Contents Vol. 27, 2006 (2006) (0)
P3.02b-006 Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients (2017) (0)
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia (2015) (0)
Management of bone metastases in breast cancer (2012) (0)
Understanding unwarranted variations of use of high-cost cancer drugs: a Comprehensive Cancer Care Network approach (2017) (0)
Erratum to: Benefit from anthracyclines in relation to biological profiles in early breast cancer (2014) (0)
[On the use of Nozinan (levomepromazine) in oncology and surgery]. (1970) (0)
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer (2018) (0)
P2-01-15: RT-PCR Gene Profiling for the Prediction of Bone Metastases in Primary Breast Cancer. (2011) (0)
18F-fluorocholine positron emission tomography/computed tomography for early outcome prediction in metastatic castration-resistant prostate cancer patients treated with enzalutamide: A proof-of-principle study. (2014) (0)
Retrospective analysis of the efficacy of somatostatin analogs (SSA) in metastatic pulmonary neuroendocrine tumors and prognostic significance of FDG-PET (2016) (0)
31st Symposium Radioactive Isotopes in Molecular Imaging (former Gastein Meeting) (2013) (0)
The role of serum chromogranin A (CgA) in patients with small cell lung cancer (2004) (0)
Accuracy of RANK/OPG and CXCR4 compared to hormone receptors in predicting bone metastases in patients with breast cancer. (2010) (0)
Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM). (1986) (0)
Abstract. Targeted therapy of metastatic colorectal cancer (mCRC) with monoclonal antibody anti-epidermal growth factor receptor (EGFR) agents, such as cetuximab (CTX) or panitumumab, is the treatment strategy of choice in patients (2015) (0)
Abstract P5-12-05:9Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER (2010) (0)
[Urinary exfoliative cytology (diagnosis of malignant tumors of the uropoietic system by means of cytologic examination o urinary smears)]. (1969) (0)
Validation of a dietary questionnaire for case-control studies (1991) (0)
Salvage treatment of relapsed or refractory germ-cell tumours. (2013) (0)
Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs (2018) (0)
Abstract 2740: Increased accuracy of TRAP-FISH combination in bladder cancer diagnosis in symptomatic patients (2010) (0)
[Gastric carcinoma: epidemiology, natural history, early diagnosis and therapy]. (1988) (0)
454 Circulating cross-linked N-telopeptide of type 1 collagen and VEGF in patients with bone metastases from breast cancer treated with zoledronic acid (2010) (0)
Abstract 2709: Peritoneal carcinomatosis from ovarian cancer: tissue markers as predictors of response to chemotherapy (2010) (0)
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study (2012) (0)
K.K. Hunt, G.L. Robb, E.A. Strom, N.T. Ueno (eds). Breast Cancer (2002) (0)
Observational prospective cohort study on fluid infusion rate and cisplatin-associated complications: Anita Zeneli and colleagues present the results of research to investigate the links between chemotherapy duration time and events such as renal toxicity (2013) (0)
Reproducibility of results on chronic pain with MC5-A Calmare® device from independent studies (2011) (0)
Intake of alternative medicine during cancer treatment and possible drug interactions. (2014) (0)
PP24 CXCR4: a predictive marker of bone metastases in breast cancer patients (2009) (0)
[Preliminary data on maintenance in vitro of gastric biopsies]. (1978) (0)
Erratum to: Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone) (2013) (0)
Genetic Analysis and Prevention (1997) (0)
Bone health management in early breast cancer patients: an Italian Osteoncology Center experience. (2017) (0)
Association of different EGFR mutations with different outcomes in EGFR-mutated NSCLC patients treated with tyrosine kinase inhibitors. (2016) (0)
Additional file 1: of eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial (2015) (0)
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report (2016) (0)
Quantitative gel retardation assay for the analysis of DNA binding of ER expressed in breast tumor cells (1995) (0)
A51Vitamin D pathway modulation in Caucasian case series of healthy women and breast cancer patients (2015) (0)
Economic burden of cancer: a population-based cost analysis. (2017) (0)
[Use of receptor data in clinical oncology]. (1987) (0)
[Cytosol CEA: a prognosis factor in breast carcinoma? (personal experience with 76 cases)]. (1990) (0)
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study. (1987) (0)
Prognosis of hepatocellular carcinoma(HCC) in Italian patients: A multiple regression analysis (1990) (0)
Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs (2017) (0)
Abstract LB-347: A microRNA signature harbors prognostic implications in clear cell renal carcinoma (ccRC) (2011) (0)
Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients? (2014) (0)
R10Disease prevalence, tumour stage, and results of testing in the pilot phase of a service for cervical cancer screening and diagnosis in northern Tanzania (2015) (0)
6571 POSTER Open-label study of pemetrexed (P) alone or in combination with a platinum in patients (pts) with peritoneal mesothelioma (PM): results from the international expanded access program (EAP) (2007) (0)
The Comprehensive Cancer Care Network of Romagna: The Opportunities Generated by the OECI Accreditation Program (2015) (0)
Is Androgen Receptor a predicitive biomarker of response to antiestrogen therapy in advanced breast cancer? (2017) (0)
Additional file 3: of eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial (2015) (0)
Activity of sorafenib used singly or in combination with other cytotoxic drugs in gastric cancer cell lines: a preclinical study (2008) (0)
Chemoprevention in oncology: Foreword (1994) (0)
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer (2017) (0)
[Mastopathy and associated histological changes, in relation to mammary carcinoma: cytological findings]. (1973) (0)
5149 Randomized phase II trial of preoperative chemotherapy plus lapatinib, trastuzumab or both in HER2 positive breast cancer: results of the first step simon's design (2009) (0)
Estrogenic Recruitment Followed by Chemotherapy in Breast Cancer: Experimental and Clinical Results (1987) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dino Amadori?

Dino Amadori is affiliated with the following schools:

Prince of Songkla University
Institute of Cancer Research
University of Modena and Reggio Emilia
University of Sassari
University of Genoa
University of Milano-Bicocca
University of Bologna